Financial Performance - Revenue for Q3 2020 was SGD 10,657,000, a decrease of 5.9% compared to SGD 11,328,000 in Q3 2019[17] - Gross profit for Q3 2020 was SGD 2,444,000, down from SGD 2,575,000 in Q3 2019, reflecting a gross profit margin of approximately 22.9%[17] - Profit from operations for Q3 2020 was SGD 448,000, compared to SGD 1,162,000 in Q3 2019, indicating a decline of 61.5%[17] - The company reported a profit before taxation of SGD 437,000 for Q3 2020, down from SGD 1,162,000 in the same period last year[17] - Earnings per share for Q3 2020 were 0.04 cents, compared to 0.36 cents in Q3 2019[17] - Total comprehensive income for the period was SGD 357,000, a significant decrease from SGD 1,162,000 in Q3 2019[17] - Revenue for Q3 2020 was SGD 10,657,000, a decrease of 5.9% from SGD 11,328,000 in Q3 2019[43] - Tissue products revenue decreased to SGD 9,079,000 in Q3 2020 from SGD 10,053,000 in Q3 2019, representing a decline of 9.7%[43] - Profit attributable to equity holders of the Company increased to SGD 357,000 in Q3 2020, compared to SGD 202,000 in Q3 2019, marking a growth of 76.7%[61] - Basic earnings per share for Q3 2020 was 0.04 cents, up from 0.03 cents in Q3 2019, reflecting a 33.3% increase[61] - Cost of sales amounted to $8.2 million, a decrease of 6.2% from $8.8 million in the Previous Period[70] - Profit for the Relevant Period was $357,000, compared to $202,000 in the Previous Period, attributed to sales of non-tissue products and government financial support[70] Expenses and Cost Management - Administrative expenses increased to SGD 1,219,000 in Q3 2020 from SGD 1,162,000 in Q3 2019, reflecting a rise of 4.9%[17] - Selling and distribution expenses were SGD 1,189,000 in Q3 2020, compared to an income of SGD 414,000 in Q3 2019, indicating a shift in expense management[17] - Staff costs increased to SGD 1,598,000 in Q3 2020 from SGD 1,401,000 in Q3 2019, an increase of 14.1%[50] - Selling and distribution expenses increased by $0.1 million or 8.9% to $1.2 million due to overall salary increases[73] - Administrative expenses were $1.2 million, reflecting a slight increase of 4.9% over the Previous Period, primarily due to salary increases[74] Future Outlook - The company continues to focus on cost control measures to mitigate the impact of declining revenues[17] - Future outlook remains cautious due to market volatility and ongoing economic challenges[17] - The company is optimistic about achieving sustainable growth and is committed to providing greater returns to shareholders[70] - The company plans to source tissue products at lower prices to manage increased costs due to rising paper pulp prices globally[70] Shareholder Information - The Board resolved not to declare any dividend for Q3 2020, consistent with Q3 2019[63] - Mr. Chua Liang Sie holds a long position of 576,000,000 shares, representing 72% of the total issued shares[82] - Ms. Chua Joo Gek also holds a long position of 576,000,000 shares, accounting for 72% of the total issued shares[82] - Mr. Chua Liang Chui similarly holds a long position of 576,000,000 shares, which is 72% of the total issued shares[82] - Mr. Chua Liang Sie is the beneficial owner of 380,000 shares, representing 65.52% of YJH Group Limited[88] - Ms. Chua Joo Gek holds 100,000 shares, which is 17.24% of YJH Group Limited[88] - Mr. Chua Liang Chui also holds 100,000 shares, accounting for 17.24% of YJH Group Limited[88] - The concert parties agreement dated October 11, 2017, deems Mr. Chua Liang Sie, Ms. Chua Joo Gek, and Mr. Chua Liang Chui as controlling YJH Group Limited as a group[91] - As of the end of the relevant period, no other directors or chief executives had registered interests in the shares or debentures of the company[92] Corporate Governance - The Company has adopted the Corporate Governance Code to ensure proper regulation of business activities and decision-making processes[124] - The Audit Committee consists of three independent non-executive Directors, ensuring appropriate oversight of financial statements[122] - The Company acknowledges the need for separation of roles between the chairman and chief executive officer, currently held by Mr. Chua since February 1990[124] - Forward-looking statements in the report reflect the Company's expectations regarding financial conditions and operational results, subject to known and unknown risks[124] - The Company will continue to review the appropriateness of the current governance structure in light of overall circumstances[124] Market and Product Development - The Group's principal activity remains the supply of tissue products to corporate customers in Singapore, with no significant seasonal impact on revenue[42] - The Group has adopted all new and revised IFRSs relevant to its operations, with no significant changes to accounting policies or financial statement presentation[41] - Sales of hygiene-related products remained stable with a slight increase of 1.5% compared to the Previous Period[70] - Sales of other products increased by $0.3 million, representing an increase of 78.7%, mainly due to the sale of face masks during the Circuit Breaker[70] - The company is considering strategic acquisitions to bolster its market position, with potential targets identified in the industry[141] - A new marketing strategy has been implemented, aiming to increase brand awareness and customer loyalty, projected to improve sales by FF%[141]
日光控股(08451) - 2020 Q3 - 季度财报